Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro11See Editorial by Towler, p. 2467.  by Yang, Hsueh et al.
Kidney International, Vol. 66 (2004), pp. 2293–2299
Elevated extracellular calcium levels induce smooth muscle cell
matrix mineralization in vitro1
HSUEH YANG, GABRIELLE CURINGA, and CECILIA M. GIACHELLI
Department of Bioengineering, University of Washington, Seattle, Washington; and Department of Pathology,
University of Washington, Seattle Washington
Elevated extracellular calcium levels induce smooth muscle cell
matrix mineralization in vitro.
Background. Hyperphosphatemia, elevated calcium × phos-
phorus product (Ca × P), and calcium burden, major causes of
vascular calcification, are correlated with increased cardiovas-
cular morbidity and mortality in dialysis patients.
Methods. To address the underlying mechanisms responsible
for these findings, we have utilized an in vitro human smooth
muscle cell (HSMC) model of vascular calcification. Previous
studies using this system demonstrated enhanced calcification
of HSMC cultures treated with phosphorus levels in the hy-
perphosphatemic range, and implicated a sodium-dependent
phosphate cotransport-dependent mechanism in this effect. In
the present study, we examine the effect of increasing calcium
concentrations on HSMC calcification in vitro.
Results. Increasing calcium to levels observed in hypercal-
cemic individuals increased mineralization of HSMC cultures
under normal phosphorus conditions. Importantly, at these total
calcium concentrations, ionized calcium levels increased from
1.2 mmol/L to 1.7 mmol/L, consistent with levels observed phys-
iologically in normocalcemic and hypercalcemic individuals,
respectively. Furthermore, increasing both calcium and phos-
phorus levels led to accelerated and increased mineralization in
the cultures. Calcium-induced mineralization was dependent on
the function of a sodium-dependent phosphate cotransporter,
since it was inhibited by phosphonoformic acid (PFA). While el-
evated calcium did not affect short-term phosphorus transport
kinetics, long-term elevated calcium treatment of HSMCs in-
duced expression of the sodium-dependent phosphate cotrans-
porter, Pit-1.
Conclusion. These studies suggest that elevated calcium may
stimulate HSMC mineralization by elevating Ca x P product
and enhancing the sodium-dependent phosphate cotransporter-
dependent mineralization pathway previously observed in
HSMCs.
1See Editorial by Towler, p. 2467.
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Over the last few years, a number of studies have fo-
cused on the clinical significance of vascular calcification
in chronic kidney disease (CKD). Nearly half the deaths
in dialysis patients are due to cardiovascular disease [1].
In CKD patients, vascular calcification is significantly as-
sociated with coronary ischemic disease [2]. In addition,
increased vascular calcification in CKD patients leads
to increased arterial wall stiffness and increased pulse
pressure both correlating with enhanced cardiovascular
mortality in CKD patients [3, 4, 5]. Furthermore, cardiac
valve and myocardial calcification are also increased and
probably contribute to morbidity and mortality in dialysis
patients [6]. Finally, severe medial calcification of small
arterioles leads to calciphylaxis, a rare but often fatal syn-
drome of ischemic necrosis of the skin and adjacent tis-
sues seen almost exclusively in uremic patients [7]. Thus,
understanding regulation and potentially controlling vas-
cular calcification in CKD patients is a high priority.
Vascular calcification is currently recognized as a cell
regulated process caused by loss of calcification inhibitors
and involving osteoblast/chondroblast-like changes in
vascular cell gene expression patterns and matrix de-
velopment (see review in [8]). Stimuli inducing these
changes as well as mechanisms for induction are currently
under intense investigation. In CKD patients, hyperphos-
phatemia and elevated calcium x phosphorus (Ca × P)
are prevalent and correlate with vascular calcification [2].
Hyperphosphatemia as well as elevated Ca × P product
have been linked to the increased cardiovascular mortal-
ity risk observed in dialysis patients in a growing num-
ber of studies [2, 9, 10]. In addition, serum calcium as
well as total calcium load (defined as daily amount of el-
emental calcium ingested) is often elevated in patients
taking calcium-containing phosphorus binders. Hyper-
calcemia is highly correlated with vascular calcification
in people as well as experimental animals [11]. Impor-
tantly, several recent studies have shown that increased
calcium load (even in the absence of hypercalcemia) is
also highly associated with vascular calcification in end-
stage renal disease (ESRD) patients. Goodman et al [12]
showed that coronary artery calcification was common
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and progressive in ESRD patients less than 30 years old,
and highly correlated with daily intake of calcium. Like-
wise, Guerin et al [13] associated arterial and aortic stiff-
ening and vascular calcification with prescribed dose of
calcium-based phosphorus binders. Finally, a recent ran-
domized clinical trial comparing a noncalcium contain-
ing phosphorus binder (sevelamer) with calcium-based
phosphorus binders in a large hemodialysis patient group
found that patients receiving sevelamer had median coro-
nary artery and aorta calcification scores unchanged after
1 year as opposed to calcium-treated patients whose coro-
nary arterial calcification scores increased 28% over base-
line [14]. Significantly, while both treatments controlled
phosphorus levels equivalently, treatment with calcium-
containing binders led to an increased frequency of hy-
percalcemic episodes and greater suppression of serum
parathyroid hormone (PTH) levels in hemodialysis
patients.
These findings have prompted us to determine whether
elevated calcium, phosphorus, or Ca × P directly affect
the potential of smooth muscle cells to mineralize their
matrices. We previously showed that elevated phospho-
rus stimulates phosphorus uptake in smooth muscle cells
(SMC) via a sodium-dependent phosphate cotransporter
resulting in mineralization and phenotypic modulation
of vascular SMC (VSMC) cultures to mineralizing cells
with osteoblast/chondrocyte-like features [15, 16]. In the
present study, we have addressed the effect of increasing
calcium in regulating SMC mineralization in vitro.
METHODS
Reagents
Dulbecco’s modified Eagle’s medium (DMEM) (high
glucose, 4.5 g/L of glucose) and fetal bovine serum (FBS)
were purchased from Life Technologies, Inc. (Grand
Island, NY, USA). Calcium-free media was purchased
from Invitrogen (Carlsbad, CA, USA). All chemicals
were reagent grade.
Cell culture
Human SMCs (HSMCs) were obtained by enzymatic
digestion of fetal and newborn aortas as previously de-
scribed [17]. Briefly, medial tissues were separated from
segments of fetal and newborn aorta obtained at au-
topsy. Small pieces of tissue (1 to 2 mm3) were digested
overnight in DMEM supplemented with 165 U/mL colla-
genase type I, 15 U/mL elastase type III, and 0.375 mg/mL
soybean trypsin inhibitor at 37◦C. Single cell suspensions
were placed in 6-well plates and cultured for several
weeks in DMEM supplemented with 20% fetal calf serum
(FCS) at 37◦C in a humidified atmosphere containing 5%
CO2. Cultures that formed colonies were collected at con-
fluence and maintained in growth medium (DMEM con-
taining 15% FBS and 1 mmol/L sodium pyruvate sup-
plemented with 100 U/mL of penicillin and 100 mg/mL
of streptomycin; final inorganic phosphorus concentra-
tion = 1.4 mmol/L). Purity of cultures was assessed
by positive immunostaining for a-smooth muscle actin
(a-SMA) and calponin, and absence of von Willebrand
factor. Fetal or newborn HSMC cultures were immortal-
ized using the HPV-E6E7 (HFSMCE6E7) as previously
described [17] and were used between passages 20 and
30. We have previously determined that immortalization
of HSMC does not affect the mineralization capability of
these cells, which was comparable to human adult aortic
SMC [15].
HSMC were cultured in DMEM containing 2 mmol/L
(final concentration) calcium chloride supplemented with
15% FBS and 100 U/mL penicillin and 100 mg/mL strep-
tomycin (growth medium) as described previously [15].
In some experiments, calcium-free DMEM was supple-
mented with calcium chloride to achieve concentrations
stated in the text.
Induction of calcification
HSMC were routinely subcultured in growth medium.
At confluence, the cells were switched to the growth
medium containing indicated amounts of inorganic phos-
phorus (adjusted by addition of appropriate amounts of
sodium phosphate) and calcium chloride for up to 12 days.
The medium was changed every 2 days. For all the calci-
fication experiments, the first day of culture in the calci-
fication medium was defined as day 0.
Quantification of calcium deposition
The calcium content was measured using the Sigma
Calcium Kit (Sigma Chemical Co., St. Louis, MO, USA)
as previously described [15]. Briefly, cells were decalci-
fied with 0.6 N HCl for 24 hours. The calcium content of
HCl supernatants was determined colorimetrically by the
o-cresolphthalein complexone method (Sigma Chemical
Co.). After decalcification, the cells were washed three
times with phosphate-buffered saline (PBS) and solu-
bilized with 0.1 N NaOH/0.1% sodium dodecyl sulfate
(SDS). The protein content was measured with the BCA
Protein Assay Kit (Pierce, Rockford, IL, USA). The cal-
cium content of the cell layer was normalized to total
cellular protein.
Determination of spontaneous calcium phosphorus
precipitation in culture media
Spontaneous calcium phosphorus precipitation was
measured by incubating normal growth media and me-
dia with increased Ca x P concentrations in 6-well plates
at 37◦C for 7 to 10 days in the absence of cells. Me-
dia were then collected and centrifuged for 5 minutes
at 14,000 × g. The supernatant was carefully aspirated
and the pellet was dissolved in 0.6 N HCl and measured
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with the Sigma Diagnostics colorimetric calcium assay as
described above.
Determination of calcium levels
Total calcium in media was determined using atomic
absorption performed on Solaar 989 analyzer. Total inor-
ganic phosphorus was measured on the Synchron LX20
Pro Analyzer. Ionized calcium was measured on an
AVL 9180 Electrolyte Analyzer. All determinations were
made in media prior to incubation with cells. All analyses
were performed by the Research Testing Services in the
Department of Laboratory Medicine at the University of
Washington.
Phosphorus transport assays
Cells were seeded at 105cells/well in 24-well plates.
At confluence (24 hours after seeding), transport studies
were performed at 37◦C in Earle’s buffered salt solution
(EBSS) with 15 mmol/L Hepes adjusted to pH 7.4. The
composition of this solution was 143 mmol/L sodium or
choline, 5.36 mmol/L potassium, 0.8 mmol/L magnesium,
2 mmol/L calcium, and 125 mmol/L chloride. The cells
were washed two times with warm EBSS before the trans-
port assay was started. Transport was initiated by adding
0.5 mL of the above medium containing the labeled sub-
strate H332PO4 (1 l Ci/mL) to HSMCs at confluence [15].
After various incubation times, the uptake was stopped
by washing the cell monolayer three times with 1 mL of
ice-cold stop solution (containing 137 mmol/L NaCl, 14
mmol/L Tris, and 10 mmol/L sodium arsenate). The cells
were solubilized with 0.5 mL of 0.1 N NaOH/0.1% SDS,
and the radioactivity of 50 uL aliquots was counted by
standard liquid scintillation techniques. Protein concen-
trations were determined with the BCA Protein Assay
Kit (Pierce). Finally, the data were normalized to the pro-
tein content.
Quantification of mRNA levels
Real-time polymerase chainr reaction (PCR). cDNA
was generated by reverse transcription of HSMC mRNA
and was amplified using ABI Prism7000 Sequence De-
tection System according to the manufacturer’s sugges-
tion. The Primer Express software (Applied Biosystems,
Inc., Foster City, CA, USA) was used to design the PCR
primers and the TaqProbe. All the primers were syn-
thesized by Qiagen Inc. (Valencia, CA, USA) and the
Taq probes were obtained from Applied Biosystems.
All Taq probes had a FAM (fluorochrome reporter)
tag at the 5′-end and a MGB (minor groove binder)
quencher at the 3′-end. The primers for human type III
sodium-dependent phosphate cotransporter (NPC), Pit-1
(Glvr-1) were forward 5′-GGAGGGTGTCAAGTGGT
CTG AA-3′ and reverse 5′-ATCTGCCTTATGGAGG
ATGAATG-3′. The Pit-1 probe is 5′-CTGATAAAAAT
TGTGATGTCTTGG-3′. The primers for human alka-
line phosphatase (ALP) were forward 5′-GAACGAGG
TCACCTCCATCCT-3′, reverse 5′-TCTCGTGGTGGT
CACAATGC-3′. The human ALP probe is 5′-ACGC
TGGGAAATC-3′. The primers for the real-time PCR
were used at final concentrations of 400 nmol/L and the
probes were used at final concentrations of 250 nmol/L.
Quantification of gene expression relative to 18S rRNA
was calculated using the Ct method according to the
manufacturer’s instructions (Applied Biosystems). 18S
rRNA was amplified using TaqMan ribosomal RNA con-
trol reagents (Applied Biosystems).
Quantitative reverse transcriptase PCR. Human Pit-1
cDNA was amplified using the following primer se-
quences: forward 5′-TACCATCCTCATCTCGGTGG-
3′, reverse 5′-TGACGGCTTGACTGAACTGG-3′.
Northern blotting. Cbfa1 mRNA levels were deter-
mined by Northern blotting exactly as previously de-
scribed [15].
RESULTS
We previously characterized an in vitro HSMC miner-
alization model that mimics several aspects of vascular
calcification observed in vivo, including apatite deposi-
tion in and around collagen fibrils, matrix vesicle for-
mation, and agglomeration of apatite crystals to large
aggregates [15]. Consistent with previous studies, we
found that elevated inorganic phosphorus was a good
inducer of HSMC mineralization (Fig. 1A). No apatite
accumulated in cultures treated with normal levels of
phosphorus (1.4 mmol/L) and calcium (2.0 mmol/L),
while increasing phosphorus concentrations to hyper-
phosphatemic levels (2.6 mmol/L) dramatically increased
calcium accumulation in the HSMC cultures.
To determine whether calcium concentration affected
HSMC mineralization, we examined matrix calcification
in response to treatment with extracellular calcium levels
similar to those observed in hypercalcemia. In all cases
the final mmol/L calcium concentration was calculated
based on the molarity of calcium chloride added. As
shown in Figure 1B, treatment of cells cultured in normal
phosphorus-containing media (1.4 mmol/L; 4.3 mg/dL)
with total calcium concentrations of 2.0 mmol/L
(8.0 mg/dL) to 3.0 mmol/L (12.0 mg/dL) led to ionized
calcium levels of 1.2 mmol/L (4.8 mg/dL) to 1.7 mmol/L
(6.8 mg/dL), respectively, as determined by calcium-
sensitive electrode. Importantly, cells treated with
increased calcium levels (2.6 and 3.0 mmol/L) and nor-
mal phosphorus levels (1.4 mmol/L) deposited increased
extracellular mineral, indicating that increasing calcium
alone could affect the potential of HSMCs to mineralize
(Fig. 1B). Finally, if both calcium and phosphorus were el-
evated, a dramatic increase in calcification was observed
(Fig. 1C).
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Fig. 1. Calcium (Ca) and phosphorus (P) effects on matrix mineral-
ization of human vascular smooth muscle cells. Human smooth muscle
cells (HSMC) were treated with the indicated concentrations of to-
tal calcium and phosphorus for 12 days. Extracellular calcium deposi-
tion was measured and normalized to corresponding cellular protein.
(A) Normal calcium and increasing concentrations of phosphorus. (B)
Normal phosphorus and increasing concentrations of calcium. (C) Ele-
vated phosphorus and increasing concentrations of calcium. Values are
expressed as a mean ± SD (N = 3). Ionized levels of calcium in the
culture media were measured as described in the Methods section.
In all cases, the final media Ca × P concentrations
(prior to incubation with cells) were kept below the sol-
ubility product of calcium and phosphorus for calcium
phosphorus dibasic or tribasic, such that spontaneous
crystallization in the media did not occur. Spontaneous
precipitation of calcium phosphorus was assessed as de-
scribed in the Methods section. Levels of calcium and
phosphorus at and above 3.2 mmol/L and 2.8 mmol/L,
respectively, were not studied because they resulted in
spontaneous precipitation in the media.
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Fig. 2. Time course of smooth muscle cells (SMC) mineralization in the
presence of elevated phosphorus (P) with or without elevated calcium
(Ca). Human SMC (HSMC) were treated with elevated (2.2 mmol/L)
phosphorus and normal calcium (2.0 mmol/L) (), or high phospho-
rus and high calcium (2.6 mmol/L) (), high phosphorus/high calcium.
Extracellular matrix calcium deposition was measured at the indicated
time points and normalized to corresponding cellular protein. Values
are expressed as a mean ± SD (N = 3).
To determine whether elevated calcium levels affected
the time course of phosphorus-induced mineralization,
we cultured cells for the indicated times in 2.2 mmol/L
phosphorus and 2.0 mmol/L calcium (high phosphorus)
or 2.2 mmol/L phosphorus and 2.6 mmol/L calcium (high
phosphorus/high calcium). As shown in Figure 2, a com-
bination of elevated phosphorus and elevated calcium
accelerated mineralization in the HSMC. Significant cal-
cification was observed as early as day 3 in cultures treated
with high phosphorus and high calcium, compared to day
10 with high phosphorus alone.
To determine the relationship between Ca x P prod-
uct and HSMC mineralization, data from Figures 1 and
2 were regraphed and a linear regression analysis was
performed. As shown in Figure 3, Ca x P product was
highly correlated with calcium deposition in HSMC (R2 =
0.9811), however, the relationship was not strictly linear.
These findings confirm an important role for Ca x P in
HSMC mineralization
To determine whether elevated calcium-induced min-
eralization was cell-mediated, we performed addi-
tional experiments. Since it was previously shown that
phosphorus-induced HSMC mineralization was depen-
dent on the activity of a sodium-dependent phosphate
cotransporter [15] we tested whether an inhibitor of this
system, phosphonoformic acid (PFA), had any effect on
calcium-induced mineralization. Interestingly, PFA com-
pletely blocked calcium- as well as phosphorus-induced
mineralization in HSMC (Fig. 4). This suggested that the
observed effects of elevated calcium on HSMC mineral-
ization were cell mediated, required a sodium-dependent
phosphate cotransporter and possibly involved regula-
tion of cotransporter function, levels, or both.
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Fig. 3. Correlation between calcium (Ca) deposition into smooth mus-
cle cells (SMC) cultures and Ca × P product. Data from Figures 1 and 2
were regraphed and a regression analysis was performed. Ca × P prod-
ucts (x axis) were calculated from total calcium and P values in media
prior to incubation with cells. Extracellular matrix calcium deposition
as determined from culture lysates is shown on the y axis. A nonlinear,
positive relationship between calcium deposition and Ca × P product
was noted (R2 = 0.9811).
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Fig. 4. Effect of phosphonoformic acid (PFA) on elevated calcium
(Ca)- and elevated phosphorus (P)-induced smooth muscle cell (SMC)
mineralization. Human SMC (HSMC) were treated with the indicated
concentrations of calcium and phosphorus in either the presence () or
absence () of 0.5 mmol/L PFA for 10 days. Extracellular matrix calcium
deposition was measured and normalized to corresponding cellular pro-
tein (N = 3). Values are expressed as a mean ± SD.
To examine these possibilities, phosphorus uptake
and transporter mRNA levels were examined in HSMC
treated with elevated calcium. As shown in Figure 5,
short-term (40 minutes) elevations in extracellular cal-
cium concentration did not alter phosphorus uptake
kinetics in HSMCs. This suggested that the trans-
port function of the sodium-dependent phosphate co-
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Fig. 5. Effect of extracellular calcium (Ca) levels on phosphorus (P)
uptake in human smooth muscle cells (HSMC). HSMC were cultured
in the presence of the indicated concentrations of calcium for 24 hours.
Phosphorus uptake for 40 minutes was measured as described in the
Methods section (N = 3). Values are expressed as a mean ± SD.
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Fig. 6. Expression of Pit-1 in human smooth muscle cells (HSMC).
HSMC were cultured with the indicated concentrations of calcium (Ca)
for 10 days. Pit-1 transcript levels were measured with real-time poly-
merase chain reaction (PCR) and normalized to 18S rRNA as described
in the Methods section. Real-time PCR assays were carried out in trip-
licate and mRNA values are expressed as a mean ± SD. Results are
representative of two separate experiments measuring Pit-1 mRNA
levels, by real-time PCR (shown) or quantitative reverse transcriptase
PCR (not shown).
transporter was not enhanced by short-term elevation
of calcium. Long-term (10 days) treatment of HSMC
with elevated calcium-containing medium, however, in-
creased the levels of Pit-1 mRNA, the major sodium-
dependent phosphate cotransporter previously shown
to be expressed in HSMC [15] (Fig. 6). These studies
suggest that increasing calcium enhances HSMC mineral-
ization in a sodium-dependent phosphate cotransporter-
dependent manner and up-regulates the type III
sodium-dependent phosphate cotransporter, Pit-1.
To determine whether elevated calcium affected the
phenotypic state of HSMC, we examined Cbfa1 and
alkaline phosphatase mRNA levels at 10 days following
treatment with either 3 mmol/L calcium or 2.6 mmol/L
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phosphorus. While both mRNAs were detected in ele-
vated calcium-treated cells, levels were not different from
those observed in elevated phosphorus -treated cells as
determined by real-time PCR (relative mRNA values
for alkaline phosphatase 1.02 in elevated calcium-treated
cells versus 1.05 in elevated phosphorus-treated cells; rel-
ative mRNA values for Cbfa1 1.03 for elevated calcium-
treated cells versus 1.2 for elevated phosphorus-treated
cells).
DISCUSSION
In the present study, we have determined the effect
of elevated extracellular calcium on SMC mineralization
in vitro. Increasing calcium to levels observed in hyper-
calcemic individuals increased mineralization of HSMC
cultures under normal phosphorus conditions. Under the
conditions used, ionized calcium levels were 1.2 mmol/L
to 1.7 mmol/L, consistent with levels observed physiolog-
ically in normocalcemic and hypercalcemic individuals,
respectively. Furthermore, increasing both calcium and
phosphorus levels in the media led to accelerated min-
eralization as well as a greater extent of mineralization
in the cultures compared to elevated phosphorus alone.
Most importantly, calcium-induced mineralization were
inhibited by PFA, suggesting a cell-mediated, sodium-
dependent phosphate cotransporter-dependent mecha-
nism of mineral deposition. While elevated calcium did
not affect steady-state uptake of phosphorus in the
short-term, long-term treatment of HSMC with elevated
calcium increased levels of Pit-1 mRNA, the major
sodium-dependent phosphate transporter in HSMC.
These data support a model whereby elevations of cal-
cium, in addition to elevating the Ca × P product, en-
hance and accelerate HSMC mineralization via increased
sodium-dependent phosphate cotransporter levels.
Until recently, vascular calcification was considered
to be a passive, degenerative, and end-stage process.
However, a number of observations have challenged
this paradigm. As in bone formation, matrix vesicles,
bone morphogenetic proteins, and noncollagenous bone
matrix proteins such as osteopontin, osteonectin, osteo-
calcin, and matrix Gla protein (MGP) appear in calci-
fied vascular tissues (reviewed in [8]). Likewise, SMCs
have the capacity to express bone-related proteins such
as Cbfa1, alkaline phosphatase, osteocalcin, and osteo-
pontin and calcify their extracellular matrix under appro-
priate conditions [15, 16, 18, 19]. Furthermore, a growing
number of genes have been associated with vascular cal-
cification based on mouse mutational studies. The MGP-
null mouse shows extensive calcification of the arterial
tree, indicating that MGP, which is constitutively ex-
pressed in arterial SMCs, is normally an important in-
hibitor of vascular calcification [20]. In addition, the
KLOTHO mouse deficient in b-glucosidase [21], the car-
bonic anhydrase II mutant [22], and osteoprotegerin-null
mouse [23] all show enhanced susceptibility to vascu-
lar calcification. Finally, structures identical to bone and
bone marrow occur frequently in advanced atheroscle-
rotic lesions, calcified cardiac valves, and Monkeberg’s
sclerosis [24]. These findings suggest that vascular calci-
fication is, in fact, an actively regulated process in which
vascular cells normally prevent calcification via elabora-
tion of inhibitory molecules, and under pathologic condi-
tions, can acquire osteoblast/chondrocyte-like properties
that can contribute to outright bone formation in vessels.
Likewise, effects of metabolic imbalance on vascular
calcification were previously assumed to be mediated
entirely through elevation of Ca × P product and sub-
sequent spontaneous calcium phosphorus precipitation
and accumulation in tissues. However, our data suggest
that elevated phosphorus and calcium levels are also
able to contribute to vascular calcification directly by
regulating the susceptibility of VSMC to mineralization.
Indeed, we previously showed that phosphorus levels
similar to those observed in hyperphosphatemic pa-
tients induced SMC to undergo phenotypic transforma-
tion to an osteoblast/chondrocyte-like cell that expressed
alkaline phosphatase, osteocalcin, and Cbfa1, and miner-
alized their matrices [15, 16]. Phosphorus-induced phe-
notypic modulation and mineralization were inhibited by
PFA, indicating that a sodium-dependent phosphate co-
transporter was involved in the process [15]. These data
indicated that cellular phosphorus transport to the extra-
cellular matrix was a key step in nucleating apatite in this
model system.
In the present studies, elevated calcium stimulated
mineralization of HSMC under normal phosphorus con-
ditions, and accelerated mineralization under elevated
phosphorus conditions. Several lines of evidence suggest
that the effects of elevated calcium on mineralization are
due to both induction of phosphorus uptake as well as
elevations in Ca × P. First, calcium-induced mineraliza-
tion was inhibited by PFA, similar to phosphorus-induced
mineralization, indicating that calcium-induced mineral-
ization was also dependent on the activity of a sodium-
dependent phosphate cotransporter. Second, elevated
calcium induced expression of the sodium-dependent
phosphate cotransporter, Pit-1. Third, mRNA levels of
Cbfa1 and alkaline phosphatase in elevated calcium-
treated HSMC were similar to those observed in ele-
vated phosphorus-treated HSMC. Finally, elevated Ca ×
P strongly correlated with mineralization in HSMC. Thus,
we speculate that elevated calcium serves to enhance
phosphorus-dependent uptake in HSMC, thereby lead-
ing to enhanced apatite nucleation in the extracellu-
lar matrix (the rate-limiting step for apatite formation)
and HSMC phenotype transition. Once nucleation of ap-
atite occurs, elevated Ca × P would drive matrix min-
eralization by accelerating apatite crystal growth via
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Fig. 7. Hypothetic model for the effects of extracellular calcium (Ca)
on vascular smooth muscle cell (VSMC) matrix mineralization. Cal-
cium is proposed to stimulate vascular matrix mineralization in two
ways. First, (1) calcium stimulates synthesis of Pit-1, thereby enhanc-
ing phosphorus (P) uptake into SMC cell membranes and matrix
vesicles. Elevated intracellular phosphorus leads to SMC pheno-
typic modulation which includes upregulation of osteogenic genes
(Cbfa1, osteocalcin, and alkaline phosphatase), and generation of a
mineralization-competent extracellular matrix. In addition, increased
Pit-1 in matrix vesicles promotes phosphorus loading of matrix vesicles,
promoting nucleation of mineral within the extracellular matrix. Sec-
ond, (2) elevated calcium leads to increased Ca × P product thereby
promoting growth of apatite crystals in the matrix via thermodynamic
mechanisms.
thermodynamic mechanisms. This proposed model is de-
picted in Figure 7.
The mechanism whereby elevated calcium increases
Pit-1 mRNA levels is not yet clear. Effects of calcium
on cells may be mediated through multiple receptors.
Of particular relevance to the present studies, Chang et
al [25] recently showed that extracellular calcium en-
hanced terminal differentiation and mineralization of
osteoblast precursor cells through a calcium receptor-
sensitive mechanism. Likewise, L-type calcium channels
have been recently implicated in calcium-mediated reg-
ulation of osteoblastic differentiation [26]. Together with
our own, these studies suggest that elevated calcium
may directly affect signaling pathways that regulate the
propensity of HSMC to mineralize their matrices.
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